Skip to main content

Advertisement

Fig. 1 | Journal of Patient-Reported Outcomes

Fig. 1

From: Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

Fig. 1

Flow chart for disposition of trial patients. aThe safety population within each phase was defined as all patients who took at least one dose of the investigational product during that phase. bThe efficacy population within each phase was defined as all patients who took at least one dose of the investigational product and had at least one post-dose efficacy assessment during that phase

Back to article page